Visit StreetInsider.com at http://www.streetinsider.com/Analyst+PT+Change/Immuneering+Corporation+%28IMRX%29+PT+Lowered+to+%2415+at+Needham%2C+%27to+reflect+a+lower+probability+of+meaningful+efficacy+as+monotherapy%27/22935879.html for the full story.
